Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction

References

• Akdag Cayli Y, Sahin S, Buttini F, et al. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients. Drug Dev Ind Pharm. 2017;43:1378–1389.
   PubMed Web of Science ®Google Scholar
• Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8:295–315.
   PubMed Web of Science ®Google Scholar
• Colombo P, Traini D, Buttini F. Inhalation drug delivery: techniques and products. Chichester: Wiley-Blackwell; 2013.
   Google Scholar
• Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22:535–543.
   PubMed Web of Science ®Google Scholar
• Koerner-Rettberg C, Ballmann M. Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy. Core Evid. 2014;9:99–112.
   PubMedGoogle Scholar
• Buttini F, Rossi I, Di Cuia M, et al. Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. Int J Pharm. 2016;502:242–248.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377:1032–1045.
   PubMed Web of Science ®Google Scholar
• Buttini F, Colombo P, Rossi A, et al. Particles and powders: tools of innovation for non-invasive drug administration. J Control Release. 2012;161:693–702.
   PubMed Web of Science ®Google Scholar
• Muralidharan P, Hayes D, Mansour HM. Dry powder inhalers in COPD, lung inflammation and pulmonary infections. Expert Opin Drug Deliv. 2015;12:947–962.
   PubMed Web of Science ®Google Scholar
• Pilcer G, De Bueger V, Traina K, et al. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int J Pharm. 2013;451:112–120.
   PubMedGoogle Scholar
• Balducci AG, Bettini R, Colombo P, et al. Drug delivery strategies for pulmonary administration of antibiotics In: Nokhodchi A, Martin GP, editors. Pulmonary drug delivery, advances and challenges. Chichester: John Wiley & Sons; 2015. p. 241–261.
   Google Scholar
• Hinds WC. Aerosol technology: properties, behavior, and measurement of airborne particles. 2nd ed. New York: John Wiley & Sons; 1998.
   Google Scholar
• Belotti S, Rossi A, Colombo P, et al. Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. Int J Pharm. 2014;471:507–515.
   PubMed Web of Science ®Google Scholar
• Kale V, Ittadwar A, Gadekar S. Particle size enlargement: making and understanding of the behavior of powder (Particle) system. Syst Rev Pharm. 2011;2:79.
   Google Scholar
• Russo P, Buttini F, Sonvico F, et al. Chimeral agglomerates of microparticles for the administration of caffeine nasal powders. J Drug Deliv Sci Technol. 2004;14:449–454.
   Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50:1209–1227.
   PubMedGoogle Scholar
• Yu LX, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16:771–783.
   PubMed Web of Science ®Google Scholar
• Pallagi E, Karimi K, Ambrus R, et al. New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach. Int J Pharm. 2016;511:151–160.
   PubMed Web of Science ®Google Scholar
• Buttini F, Rozou S, Rossi A, et al. The application of quality by design framework in the pharmaceutical development of dry powder inhalers. Eur J Pharm Sci. 2018;113:64–76.
   PubMed Web of Science ®Google Scholar
• Korakianiti E, Rekkas D. Statistical thinking and knowledge management for quality-driven design and manufacturing in pharmaceuticals. Pharm Res. 2011;28:1465–1479.
   PubMed Web of Science ®Google Scholar
• N. Politis S, Colombo P, Colombo G, et al. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43:889–901.
   PubMed Web of Science ®Google Scholar
• Montgomery DC, Runger GC. Applied statistics and probability for engineers. 3rd ed. New York: John Wiley & Sons; 2003. p. 976.
   Google Scholar
• Parlati C, Colombo P, Buttini F, et al. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm Res. 2009;26:1084–1092.
   PubMed Web of Science ®Google Scholar
• Tiozzo Fasiolo L, Manniello MD, Bortolotti F, et al. Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer’s disease. J Drug Target. 2019;27:984–994.
   PubMed Web of Science ®Google Scholar
• Jong T, Li J, Hale JDF, et al. Investigating the particle engineering of colistin for pulmonary delivery. In: He J, editor. Proceedings of the 1st electronic conference on pharmaceutical sciences. Basel: MDPI; 2011. p. 1–6.
   Google Scholar
• Buttini F, Giulia A, Colombo G, et al. Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. Int J Pharm. 2018;548:182–191.
   PubMedGoogle Scholar
• Lee SH, Teo J, Heng D, et al. Synergistic combination dry powders for inhaled antimicrobial therapy. Eur J Pharm Biopharm. 2013;83:275–284.
   PubMed Web of Science ®Google Scholar
• Chow AHL, Tong HHY, Chattopadhyay P, et al. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411–437.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P, Hoppentocht M, et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14:499–512.
   PubMed Web of Science ®Google Scholar
• Zeng XM, Martin GP, C M. Particulate interactions in dry powder formulation for inhalation. 1st ed. London: CRC Press; 2000. p. 264.
   Google Scholar